A Randomized, Single-Blind, Placebo-Controlled Crossover, Dose Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of UROCORTIN II in Healthy Subjects and in Patients with moderate Congestive Heart Failure (CHF).

Trial Profile

A Randomized, Single-Blind, Placebo-Controlled Crossover, Dose Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of UROCORTIN II in Healthy Subjects and in Patients with moderate Congestive Heart Failure (CHF).

Completed
Phase of Trial: Phase I/II

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Urocortin 2 (Primary)
  • Indications Heart failure
  • Focus Adverse reactions
  • Most Recent Events

    • 15 Nov 2011 ANZCTR says trial is ph I. But MR says several phase I and two ph II trials in CHF have been completed. It appears that this must be one of the ph II trials (changed to ph I/II)
    • 02 Sep 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top